Results 101 to 110 of about 8,187 (238)

Addressing antimicrobial resistance: Structural insights into cefiderocol's mode of action and emerging resistance mechanisms.

open access: yesJournal of Infection and Public Health
Cefiderocol represents a significant advancement in the treatment of multidrug-resistant Gram-negative bacterial infections. Its unique uptake mechanism, leveraging bacterial iron transport pathways for membrane permeation, sets it apart from ...
M. Z. Salleh
semanticscholar   +1 more source

Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID.

open access: yesJournal of Infection
INTRODUCTION The increase in the population of immunocompromised patients due to advances in management of end-stage diseases and transplants poses challenges in treating infections caused by multi-drug resistant (MDR) pathogens.
Sarah Soueges   +24 more
semanticscholar   +1 more source

Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa [PDF]

open access: yes
Objectives: The main aim of this study was to evaluate the antibiofilm activity of cefiderocol alone and in combination with imipenem vs. sessile cells of Pseudomonas aeruginosa, assessing a potential synergistic bactericidal effect.
Cesta N.   +16 more
core   +1 more source

Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?

open access: yesJournal of Antimicrobial Chemotherapy
Background Carbapenemase-producing Enterobacterales (CPE) pose difficult therapeutic challenges. We aimed to characterize antimicrobial resistance profiles of CPE in our centre.
I. Baltas, Trupti Patel, A. Soares
semanticscholar   +1 more source

In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii

open access: yesMicrobiology Spectrum
The emergence and spread of third-/fourth-generation cephalosporin and/or carbapenem-resistant Acinetobacter baumannii have become a significant global public health concern, making new treatment alternatives necessary.
Barbara Ymaña   +20 more
doaj   +1 more source

Utility of a TDM-Guided Expert Clinical Pharmacological Advice Program for Optimizing the Use of Novel Beta-Lactam/Beta-Lactamase Inhibitor Combinations and Cefiderocol in a Tertiary University Hospital: An Interim Analysis

open access: yesTherapeutic Drug Monitoring
Supplemental Digital Content is Available in the Text.
M. Gatti   +6 more
semanticscholar   +1 more source

In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol

open access: yesJournal of antibiotics (Tokyo. 1968)
Cefiderocol, a novel siderophore cephalosporin, demonstrates promising in vitro activity against multidrug-resistant Gram-negative bacteria, including carbapenemase-producing strains.
Richard Kriz   +10 more
semanticscholar   +1 more source

When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada

open access: yesMicrobiology Spectrum
Gram-negative metallo-β-lactamase-producing bacteria can be extremely problematic, especially when found to be extensively drug-resistant (XDR). Cefiderocol is a novel antimicrobial that has been shown to overcome most carbapenemases, with very rare ...
Kevin R. Barker   +5 more
doaj   +1 more source

Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.

open access: yesJournal of Infection
BACKGROUND The best treatment for carbapenem-resistant Acinetobacter baumannii (CRAB) infections is still a matter of debate. OBJECTIVES To describe the outcomes of patients treated with cefiderocol for CRAB infections, and to compare the efficacy of ...
Lorenzo Onorato   +3 more
semanticscholar   +1 more source

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak

open access: yes
Variable outcomes have been reported with cefiderocol in infections due to carbapenem-resistant Acinetobacter baumannii (CRAB). Nonetheless, it may be the only option for metallo-beta-lactamase-producing strains.
Francesco Peracchi   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy